盐酸埃克替尼治疗晚期非小细胞肺癌的临床观察(4)
| 第1页 |
参见附件。
[5] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours： Revised RECIST guideline (version 1. 1) [J]. Eur J Cancer，2009，45(2)：228-247.
[6] Liang JL，Ren XC，Lin Q. Treating advanced non-small-cell lung cancer in Chinese patients： Focus on icotinib[J]. Onco Targets Ther，2014，(7)：761-770.
[7] Bai H，Wang Z，Chen K，et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer[J]. J Clin Oncol，2012，30(25)：3077-3083.
[8] Wu YL，Lee JS，Thongprasert S，et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer(FASTACT-2)： A randomized， double-blind trial[J]. Lancet Oncol，2013，14(8)：777-786.
[9] Zhao Q，Shentu J，Xu N，et al. Phase I study of icotinib hydrochloride (BPI-2009H)， an oral EGFR tyrosine kinase inhibitor， in patients with advanced NSCLC and other solid tumors[J]. Lung Cancer，2011，73(2)：195-202.
[10] Wang HP，Zhang L，Wang YX，et al. Phase I trial of icotinib， a novel epidermal growth factor receptor tyrosine kinase inhibitor， in Chinese patients with non-small cell lung cancer[J]. Chin Med J (Engl)，2011，124(13)：1933.
[11] Tan F，Shen X，Wang D，et al. Icotinib(BPI-2009H)， a novel EGFR tyrosine kinase inhibitor， displays potent efficacy in preclinical studies[J]. Lung Cancer，2012，76(2)：177-182.
[12] Gu A，Shi C，Xiong L，et al. Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer[J]. Chin J Cancer Res，2013，25(1)：90-94.
(收稿日期：2014-11-06)
您现在查看是摘要介绍页，详见PDF附件。